Karyopharm Therapeutics Inc. (KPTI), Thursday announced financial results for the fourth quarter, revealing a net loss of $102.2 million, or $5.71 per share, compared to $30.8 million, or $3.67 per share, last year.
Total revenue for the quarter increased to $34.1 million from $30.5 million in the prior year.
Moving ahead, the company expects total revenue to be in the range of $130 million to $150 million, including U.S. XPOVIO net product revenue guidance of $115 million to $130 million.
In the pre-market hours, KPTI is trading at $6.80, down 7.73 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.